STF 083010

STF 083010 Suppliers list
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +undefined-21-51877795
Email: ivan@atkchemical.com
Products Intro: Product Name:STF-083010
CAS:307543-71-1
Purity:98% Package:10MG;50MG;100MG,1G,5G,10G.100G
Company Name: career henan chemical co
Tel: +86-0371-86658258 +8613203830695
Email: factory@coreychem.com
Products Intro: Product Name:STF 083010
CAS:307543-71-1
Purity:>98% Package:1g;1USD
Company Name: InvivoChem
Tel: +1-708-310-1919 +1-13798911105
Email: sales@invivochem.cn
Products Intro: Product Name:STF-083010
CAS:307543-71-1
Purity:98% Package:5mg Remarks:V1900
Company Name: Nantong HI-FUTURE Biology Co., Ltd.
Tel: +undefined18051384581
Email: sales@chemhifuture.com
Products Intro: Product Name:STF-083010
CAS:307543-71-1
Purity:98% HPLC Package:10mg,500mg,1g,5g,10g,more
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354
Email: support@targetmol.com
Products Intro: Product Name:STF-083010;STF083010;STF 083010
CAS:307543-71-1
Package:1 mL * 10mM (in DMSO);10 mg;100 mg;20 mg;25 mg;5 mg;50 mg Remarks:REAGENT;FOR LABORATORY USE ONLY

STF 083010 manufacturers

  • STF 083010
  • STF 083010 pictures
  • $1.00 / 1g
  • 2020-01-15
  • CAS:307543-71-1
  • Min. Order: 100g
  • Purity: >98%
  • Supply Ability: g/kg/Ton
STF 083010 Basic information
Product Name:STF 083010
Synonyms:STF 083010;(E)-N-((2-hydroxynaphthalen-1-yl)methylene)thiophene-2-sulfonamide;N-[(2-Hydroxy-1-naphthalenyl)methylene]-2-thiophenesulfonamide;STF-083010;STF083010;STF 083010;CS-2595;CS-2901;2-Thiophenesulfonamide, N-[(2-hydroxy-1-naphthalenyl)methylene]-;N-((2-Hydroxynaphthalen-1-yl)methylene)thiophene-2-sulfonamide
CAS:307543-71-1
MF:C15H11NO3S2
MW:317.38
EINECS:
Product Categories:Inhibitors
Mol File:307543-71-1.mol
STF 083010 Structure
STF 083010 Chemical Properties
Melting point 199-201°C
Boiling point 548.4±56.0 °C(Predicted)
density 1.40±0.1 g/cm3(Predicted)
storage temp. -20°C
solubility DMSO: soluble5mg/mL (clear solution)
pka7.31±0.50(Predicted)
form powder
color light yellow to yellow-green
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
MSDS Information
STF 083010 Usage And Synthesis
DescriptionSTF-083010 (307543-71-1) is a novel small molecule inhibitor of IRE1. It inhibits IRE1 endonuclease activity but not its kinase activity after endoplasmic reticulum stress.1-3 It displays significant antimyeloma activity in model human MM xenografts.1?STF-083010 induces apoptosis in pancreatic cancer cells and displays growth inhibition in a clonogenic growth assay in soft agar as well as in a xenograft?in vivo model of pancreatic cancer.4?Active?in vivo.
UsesSTF 083010 is an inhibitor of Ire1 endonuclease.
UsesSTF-083010 has been used:
  • in a study to investigate the?potential?anti-lipotoxic effect of nicotinamide and to elucidate underlying mechanism(s)
  • as IRE1a inhibitor to study its effect on NOS 2 expression and investigate the underlying mechanisms in proinflammatory gene expression in astrocytes
  • to block endogenous XBP1 cleavage for one hour prior to palmitate exposure in order to examine whether inositol?requiring enzyme 1α (IRE1α ) activation is implicated in palmitate cytotoxicity

Biochem/physiol ActionsSTF-083010 is a potent inhibitor of the ER transmembrane protein IRE1, which mediates the unfolded protein response. STF-083010 inhibits IRE1 endonuclease and mRNA splicing activity in response to endopasmic reticulum (ER) stress, but has no affect on the kinase activity of IRE1.
in vitroafter endoplasmic reticulum stress both in vitro and in vivo, stf-083010 prevented ire1 endonuclease activity without affecting its kinase activity. treatment with stf-083010 exhibited significant antimyeloma activity in model human mm xenografts. similarly, compared with other similarly isolated cell populations, stf-083010 was preferentially toxic to freshly isolated human cd138 mm cells. on basis of the identification of this novel ire1 inhibitor, propose that the ire1-xbp1 axis is a promising target for anticancer therapy (especially in the context of mm) [1].
in vivothe small molecule stf083010, identified by a high-throughput screen of compounds affecting ire1 activity, was capable of directly inhibiting the endonuclease function of ire1 without affecting its kinase activity. after treatment of mice harboring subcutaneous xenografts led to tumor shrinkage and multiple myeloma cells harvested from cancer patients died following exposure to stf083010, the antimyeloma therapeutic potential of stf083010 was convincingly demonstrated [2].
storageStore at -20°C
References1) Papandreou?et al. (2011),?Identification of an Ire1α endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma; Blood,?117?1311 2) Wang?et al. (2012),?Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors; Nature Chem. Biol.,?8?982 3) Tam?et al. (2014),?Ire1 has distinct catalytic mechanisms for XBP/HAC1 splicing and RIDD; Cell Rep.,?9?850 4) Chien?et al. (2014),?Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells; Oncotarget,?5?4881
STF 083010 Preparation Products And Raw materials
Tag:STF 083010(307543-71-1) Related Product Information
Fatostatin A 2-Methoxy-4-[(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazonomethyl]-phenol N-(1-phenylethyl)-2-(pyrrolidin-1-yl)quinazolin-4-aMine PROCHLORPERAZINE MALEATE STK16-IN-1 STF-118804